Mismatch Repair Loss Renders ER+/HER2- Breast Cancer Susceptible to HER2/3 Inhibition
Technical Report,01 Mar 2019,28 Feb 2020
Sanford Burnham Prebys Medical Discovery Institute La Jolla United States
Pagination or Media Count:
The objective of this proposed study is to investigate a role for HER23 activation in MutLdefective ER breast cancer progression and resistance to endocrine therapy. By targeting HER23 signaling and key nodes of adaptive kinome response, we aim to significantly improve patient disease-specific survival.
- Medicine and Medical Research